Bapineuzumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameBapineuzumab
Drug Alias Namebapineuzumab巴匹珠单抗巴匹奈珠单抗bapineuzumabumAAB-001 SubQ +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[27] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer IncElan Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWyeth LlcJanssen Alzheimer Immunotherapy Research & Development LlcPfizer Inc +[4] 
Active IndicationsN/A
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG